Stähelin H F
Experientia. 1996 Jan 16;52(1):5-13. doi: 10.1007/BF01922409.
The immunosuppressant cyclosporin A (Sandimmune) has become the first line treatment for preventing rejection of transplanted organs and for certain autoimmune diseases. The discovery of that drug and its preclinical development are described, and it is shown that most earlier accounts of the history of this compound are, in important respects, incorrect and misleading.
免疫抑制剂环孢素A(山地明)已成为预防移植器官排斥反应和某些自身免疫性疾病的一线治疗药物。本文描述了该药物的发现及其临床前开发过程,并表明大多数关于这种化合物历史的早期记载在重要方面是不正确且具有误导性的。